Published in J Clin Immunol on July 01, 2005
The within host dynamics of Mycobacterium avium ssp. paratuberculosis infection in cattle: where time and place matter. Vet Res (2015) 0.96
Networked T cell death following macrophage infection by Mycobacterium tuberculosis. PLoS One (2012) 0.91
CD4 lymphocyte dynamics in Tanzanian pulmonary tuberculosis patients with and without HIV co-infection. BMC Infect Dis (2012) 0.89
Adequate Th2-type response associates with restricted bacterial growth in latent mycobacterial infection of zebrafish. PLoS Pathog (2014) 0.83
Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol (2009) 0.81
Cytotoxic activity of dendritic cells as a possible mechanism of negative regulation of T lymphocytes in pulmonary tuberculosis. Clin Dev Immunol (2012) 0.78
Expression of TNF-alpha-dependent apoptosis-related genes in the peripheral blood of Malagasy subjects with tuberculosis. PLoS One (2013) 0.76
Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis. J Pathol (2017) 0.75
Mycobacterium tuberculosis Induces Expansion of Foxp3 Positive CD4 T-cells with a Regulatory Profile in Tuberculin Non-sensitized Healthy Subjects: Implications for Effective Immunization against TB. J Clin Cell Immunol (2016) 0.75
HIV-1 Infection Is Associated with Depletion and Functional Impairment of Mycobacterium tuberculosis-Specific CD4 T Cells in Individuals with Latent Tuberculosis Infection. J Immunol (2017) 0.75
The Bcl-2 protein family: arbiters of cell survival. Science (1998) 16.08
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 7.52
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34
A license to kill. Cell (1996) 3.37
Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. J Clin Immunol (1992) 3.13
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med (1995) 2.28
Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J Immunol (1995) 2.21
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A (1996) 2.15
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis (1999) 2.06
Plasmodium falciparum induces apoptosis in human mononuclear cells. Infect Immun (1996) 1.50
Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis (1999) 1.44
Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis (2001) 1.43
Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells. Curr Biol (2000) 1.23
Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol (1998) 1.18
Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun (1999) 1.17
Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol (2000) 1.08
Anergy, IFN-gamma production, and apoptosis in terminal infection of mice with Mycobacterium avium. J Immunol (1999) 1.05
Hierarchical control of lymphocyte survival. Science (1996) 1.04
Autocrine expression of activated transforming growth factor-beta(1) induces apoptosis in normal rat liver. Am J Physiol Gastrointest Liver Physiol (2001) 0.96
A cytofluorometric method for the simultaneous detection of both intracellular and surface antigens of apoptotic peripheral lymphocytes. J Immunol Methods (1998) 0.92
A portrait of the Bcl-2 protein family: life, death, and the whole picture. J Clin Immunol (1999) 0.90
Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res (1998) 0.90
Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology (2000) 0.89
Induction of apoptosis in bacillus Calmette-Guérin-activated T cells by transforming growth factor-beta. Cell Immunol (2000) 0.78
Synergistic induction of apoptosis in primary CD4(+) T cells by macrophage-tropic HIV-1 and TGF-beta1. J Immunol (2001) 0.77
Mycobacterium tuberculosis induces apoptosis in gamma/delta T lymphocytes from patients with advanced clinical forms of active tuberculosis. Clin Diagn Lab Immunol (1997) 0.77
Synergistic action between tumor necrosis factor-alpha and transforming growth factor type-beta: consequences for natural antitumor mechanisms. Anticancer Res (2000) 0.75
Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol (2009) 12.98
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 4.58
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol (2005) 3.00
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92
Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med (2003) 2.59
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLoS One (2009) 2.09
Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav (2006) 2.08
Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS (2014) 2.05
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med (2009) 2.03
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med (2014) 2.00
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav (2006) 1.83
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2007) 1.72
Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ (2004) 1.69
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS (2004) 1.65
Hypoglycemia at admission is associated with inhospital mortality in Ugandan patients with severe sepsis. Crit Care Med (2011) 1.64
Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol (2007) 1.64
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis (2005) 1.63
Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr (2014) 1.61
Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis (2002) 1.59
Impact of HIV antiretroviral therapy on depression and mental health among clients with HIV in Uganda. Psychosom Med (2012) 1.58
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2004) 1.58
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 1.58
Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis (2013) 1.56
Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med (2012) 1.55
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Factors associated with intention to conceive and its communication to providers among HIV clients in Uganda. Matern Child Health J (2012) 1.50
Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One (2011) 1.50
Point-of-care lactate testing predicts mortality of severe sepsis in a predominantly HIV type 1-infected patient population in Uganda. Clin Infect Dis (2008) 1.48
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med (2008) 1.47
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother (2010) 1.45
Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis (2003) 1.44
Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One (2008) 1.41
A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis (2004) 1.39
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev (2002) 1.36
Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One (2010) 1.35
Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis (2005) 1.35
Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol (2002) 1.35
Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. BMC Infect Dis (2010) 1.34
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis (2011) 1.29
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol (2002) 1.29
Resurrecting the triple threat: academic social responsibility in the context of global health research. Clin Infect Dis (2009) 1.29
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol (2002) 1.27
HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis. J Immunol (2006) 1.26
Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg (2006) 1.26
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS (2007) 1.26
Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun (2005) 1.24
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2009) 1.24
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One (2013) 1.24
Potential for false positive HIV test results with the serial rapid HIV testing algorithm. BMC Res Notes (2012) 1.24
A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda. AIDS Patient Care STDS (2009) 1.24